Regardless of the absence of a survival benefit, the tumour MGMT activity results lend validity to the basic premise of the RTOG 0525 trial and other ongoing trials using dose-intense temozolomide regimens in the treatment of newly diagnosed or refractory glioblastoma. This evidence concerns the gene MGMT and glioblastoma.